Amphastar Pharmaceuticals AMPH Finished Pharmaceutical Products — Goodwill
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's finished pharmaceutical products — goodwill.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's finished pharmaceutical products — goodwill?
- Amphastar Pharmaceuticals (AMPH) reported finished pharmaceutical products — goodwill of $3.33M in Q1 2026.
- How has Amphastar Pharmaceuticals's finished pharmaceutical products — goodwill changed year-over-year?
- Amphastar Pharmaceuticals's finished pharmaceutical products — goodwill increased by 5.5% year-over-year, from $3.16M to $3.33M.
- What is the long-term trend for Amphastar Pharmaceuticals's finished pharmaceutical products — goodwill?
- Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's finished pharmaceutical products — goodwill has grown at a -1.7% compound annual growth rate (CAGR), from $14.33M to $13.36M.
- What does finished pharmaceutical products — goodwill mean?
- This represents the intangible asset value recorded when the cost of an acquired business unit exceeds the fair value of its identifiable net assets. It reflects the premium paid for expected future economic benefits, such as brand reputation, customer relationships, and proprietary technology within the finished pharmaceutical products segment.